Jessica C. Hassel, MD, on Uveal Melanoma: Comparing Tebentafusp With Standard Therapies
Source: The ASCO Post, 2021
Jessica C. Hassel, MD, of University Hospital Heidelberg, discusses phase III results of a study that compared tebentafusp, a bispecific fusion protein, with investigator’s choice in patients with metastatic uveal melanoma. Tebentafusp nearly halved the risk of death among patients in the trial with this rare eye cancer (Abstract CT002).
